WW
NBIX icon

Winnow Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Winnow Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$971K Sell
5,759
-191
-3% -$28.3K 0.66% 43
2026
Q1 		$784K Sell
5,950
-312
-5% -$41.4K 0.6% 61
2025
Q4 		$889K Sell
6,262
-548
-8% -$79.4K 0.66% 59
2025
Q3 		$960K Buy
+6,810
New +$923K 0.75% 55
2025
Q2 		– Sell
-6,697
Closed -$741K – 497
2025
Q1 		$741K Buy
6,697
+1,336
+25% +$169K 0.68% 58
2024
Q4 		$707K Buy
+5,361
New +$663K 0.7% 46

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Winnow Wealth's NBIX Position: Q2 2026 in Review

Winnow Wealth reduced its Neurocrine Biosciences (NBIX) stake by 3.2% in Q2 2026, selling an estimated $28.3K and leaving 5,759 shares worth $971K. The position accounts for 0.66% of the portfolio, ranked #43.

Winnow Wealth first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Winnow Wealth held 5,759 shares of Neurocrine Biosciences worth $971K as of Q2 2026.
  • Winnow Wealth sold 191 Neurocrine Biosciences shares in Q2 2026, an estimated $28.3K.
  • Neurocrine Biosciences made up 0.66% of Winnow Wealth's portfolio in Q2 2026, its #43 holding.
  • Winnow Wealth first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Winnow Wealth's 13F filing for Q2 2026, filed 22 Jul 2026.